Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU011248 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks |
| Arm 2 | PLACEBO_COMPARATOR | 1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment. |
| Name | Type | Description |
|---|---|---|
| SU011248 | DRUG | 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression |
| Placebo | DRUG | 50 mg capsule OD PO for 28 days then 14 days rest until disease progression |
Inclusion Criteria: * Histologically/cytologically proven inoperable, metastatic or recurrent transitional cell carcinoma of the urothelial tract * Mixed histology with predominant TCC allowed. * Failed, intolerant or ineligible for cisplatin based chemo * Measurable Disease (RECIST)Not previously ...
SU011248 is an investigational small molecule being studied for the treatment of urothelial cancer, also referred to as bladder cancer, in adults. It is currently in Phase 2 clinical development and has been evaluated in a completed clinical trial for this indication.
SU011248 is being developed by Avalon GloboCare Corp., a biopharmaceutical company traded under the ticker symbol ALBT. The company is conducting clinical research on this investigational drug for the treatment of urothelial cancer.
SU011248 is in Phase 2 clinical development. It has completed one Phase 2 trial for urothelial cancer, and it remains an investigational drug that has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical studies.
SU011248 has been studied in one completed Phase 2 clinical trial, identified as NCT00578526, titled 'SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial.' This trial enrolled 64 participants with urothelial or bladder cancer in Canada and was placebo-controlled.
SU011248 is the investigational code name for the drug also known as sunitinib. It is a small molecule being studied for its potential use in treating urothelial cancer, and it has been evaluated in a Phase 2 clinical trial for this condition.